These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of relapsed/refractory disease.

New promising combinations of chemoimmunotherapy with antibody drug conjugates, and small molecule inhibitors may offer an alternative approach for patients with relapsed or refractory disease. Many of these new therapies are oral and will be managed by a multidisciplinary team.

There is a clear need to educate clinicians regarding the special considerations for the administration of CAR T-cell therapy in appropriately selected patients, the unique spectrum of adverse events and effective management strategies.

CAR T-cell therapy represents a novel class of immunotherapy and its use has been expanding in relapsed or refractory hematologic malignancies. To ensure optimal patient outcomes, treatment-related toxicities must be closely monitored and quickly managed.

New promising combinations of chemoimmunotherapy with antibody drug conjugates, and small molecule inhibitors may offer an alternative approach for patients with relapsed or refractory disease. Many of these new therapies are oral and will be managed by a multidisciplinary team.

Clinicians who treat pediatric BL and DLBCL need to be informed about the recommendations in the new NCCN Guidelines for Pediatric Aggressive Mature B-Cell Lymphomas so that they can appropriately stratify patients into risk groups, plan initial therapy, and manage common supportive care issues. They also need information on recommended surveillance protocols and treatment of relapsed/refractory disease.

This is a potentially curable malignancy and systemic therapy is the mainstay of treatment. Understanding the diagnosis, workup, and subsequent treatment for early stage and later stage disease will improve understanding and subsequently, education for patients and caregivers alike.

Clinicians who treat pediatric BL and DLBCL need to be informed about the recommendations in the new NCCN Guidelines for Pediatric Aggressive Mature B-Cell Lymphomas so that they can appropriately stratify patients into risk groups, plan initial therapy, and manage common supportive care issues. They also need information on recommended surveillance protocols and treatment of relapsed/refractory disease.

There is a clear need for clinicians to receive education regarding the special considerations for the administration of CAR T-cell therapy in appropriately selected patients, the unique spectrum of treatment-related adverse events and the effective management strategies. More importantly, clinicians should refer appropriate patients for participation in well-designed clinical studies to facilitate the development of CAR T-cell therapies. 

Educating clinicians about the biology of MZLs, novel therapeutic approaches and special considerations will help them to develop an individualized treatment plan to optimize clinical outcomes.